OncoMatch/Clinical Trials/NCT06839144
Inhibiting Beta-adrenergic and COX-2 Signaling During the Perioperative Period to Reduce Ovarian Cancer Progression
Is NCT06839144 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies Propranolol (Beta-Blocker) and Etodolac (COX-2 Inhibitor) for ovarian cancer.
Treatment: Propranolol (Beta-Blocker) and Etodolac (COX-2 Inhibitor) — This study investigates the impact of perioperative inhibition of beta-adrenergic and COX-2 signaling in ovarian cancer patients undergoing debulking surgery. The trial aims to assess the feasibility, safety, and biological effects of a combination of propranolol and etodolac in reducing cancer metastasis and improving immune responses.
Check if I qualifyExtracted eligibility criteria
Cancer type
Ovarian Cancer
Disease stage
Metastatic disease required
Ovarian Cancer Metastatic Recurrent
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Lab requirements
Kidney function
renal failure, measured by creatinine level >1.5
Liver function
significant liver dysfunction (known cirrhosis, Bilirubin level>2)
Cardiac function
significant heart failure (NYHA functional class 3 or Higher); bradycardia (heart rate of 50 or less); second- or third-degree AV block; right-sided heart failure owing to pulmonary hypertension; Printzmetal's angina; significant diagnosed cardiomegaly; sick sinus syndrome; peripheral vascular disease
Patients with significant liver dysfunction (known cirrhosis, Bilirubin level>2); Patients with renal failure, measured by creatinine level >1.5; Patients with significant heart failure (NYHA functional class 3 or Higher); bradycardia (heart rate of 50 or less); second- or third-degree AV block; right-sided heart failure owing to pulmonary hypertension; Printzmetal's angina; significant diagnosed cardiomegaly; sick sinus syndrome; peripheral vascular disease
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify